Skip to content
10-Q

Quarterly Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001493152-24-044720

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 11, 2024 420.28M sh
Stockholders Equity Q3 2024 · Sep 30, 2024 −$5.42M
Stockholders Equity Q3 2024 · Jun 30, 2024 −$7.51M
Stockholders Equity Q3 2024 · Mar 31, 2024 −$7.45M
Stockholders Equity Q3 2024 · Dec 31, 2023 −$7.59M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$7.52M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$7.3M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$7M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$6.23M
Current Liabilities Q3 2024 · Sep 30, 2024 $6.22M
Current Liabilities Q3 2024 · Dec 31, 2023 $9.02M
Total Liabilities Q3 2024 · Sep 30, 2024 $6.22M
Total Liabilities Q3 2024 · Dec 31, 2023 $9.04M
Current Assets Q3 2024 · Sep 30, 2024 $760K
Current Assets Q3 2024 · Dec 31, 2023 $1.36M
Total Assets Q3 2024 · Sep 30, 2024 $802.03K
Total Assets Q3 2024 · Dec 31, 2023 $1.45M
Net Income Q3 2024 · Jun 30, 2024 −$846.85K
Net Income Q3 2024 · Mar 31, 2024 −$504.04K
Net Income Q3 2024 · Sep 30, 2023 −$775.84K
Net Income Q3 2024 · Sep 30, 2023 −$2.44M
Net Income Q3 2024 · Jun 30, 2023 −$835.06K
Net Income Q3 2024 · Mar 31, 2023 −$827.45K
Shares Diluted Q3 2024 · Sep 30, 2023 419.52M sh
Shares Diluted Q3 2024 · Sep 30, 2023 419.5M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$2.01M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $367.25K
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.01
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Eps Basic Q3 2024 · Sep 30, 2023 −$0.01
Sga Expense Q3 2024 · Sep 30, 2023 $433.09K
Sga Expense Q3 2024 · Sep 30, 2023 $1.4M
Rd Expense Q3 2024 · Sep 30, 2023 $350.79K
Rd Expense Q3 2024 · Sep 30, 2023 $1.33M
Operating Income Q3 2024 · Sep 30, 2023 −$714.15K
Operating Income Q3 2024 · Sep 30, 2023 −$2.3M
Revenue Q3 2024 · Sep 30, 2023 $69.73K
Revenue Q3 2024 · Sep 30, 2023 $436.6K